Source: https://patents.google.com/patent/ES2340616T3/en
Timestamp: 2020-01-19 19:55:35
Document Index: 645330667

Matched Legal Cases: ['arts 30', 'art 30', 'art 36', 'art 36', 'art 38', 'art 36', 'art 36']

ES2340616T3 - Ophthalmological implant and method for sustained release of measurement to the eye. - Google Patents
Ophthalmological implant and method for sustained release of measurement to the eye. Download PDF
ES2340616T3
ES2340616T3 ES07012726T ES07012726T ES2340616T3 ES 2340616 T3 ES2340616 T3 ES 2340616T3 ES 07012726 T ES07012726 T ES 07012726T ES 07012726 T ES07012726 T ES 07012726T ES 2340616 T3 ES2340616 T3 ES 2340616T3
ES07012726T
Bruce E. Cohan
1999-04-19 Priority to US09/294,720 priority Critical patent/US6196993B1/en
1999-04-19 Priority to US294720 priority
2000-04-07 Application filed by EYELAB GROUP LLC filed Critical EYELAB GROUP LLC
2008-05-15 First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23134640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2340616(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
2010-06-07 Application granted granted Critical
2010-06-07 Publication of ES2340616T3 publication Critical patent/ES2340616T3/en
Ophthalmic implant for the sustained release of medication to one eye, the implant having a body part sized to pass through a tear point and to be placed inside a tear canalicle of an eyelid, a collarette connected to the body part and sized to rest on the outside of the lacrimal point, the collarette having at least one pore provided therein, a deposit contained at least partially within the body part and in fluid communication with the at least one pore, where the use comprises the stages of : Place the implant inside the eyelid tear canal and canalicle; and release the medication stored inside the reservoir through at least one pore and into the eye over time in a manner.
Ophthalmic implant and method for sustained release of medication to the eye.
This invention relates to an implant. ophthalmological and a method for sustained release of Eye medication for the treatment of eye disorders.
In order to treat the infection, the inflammation, glaucoma and other eye diseases, it is often It is necessary to administer drugs to the eye. A conventional method of Drug administration is by topical application to the eye surface The eye is exceptionally suitable for this route of administration of the drug on the surface because, properly constituted, drugs can penetrate through of the cornea, increase therapeutic concentration levels inside the eye and exert its beneficial effects. In practice, eye drops currently constitute more than 95% of the methods of administration of drug for the eye. On rare occasions Eye drugs are administered orally or by injection, or because they reach the eye in a concentration too low to have the desired pharmacological effect, or because its use is complicated by side effects Systemic significant.
Eye drops, although effective, is little perfected and is inefficient. When a drop of is instilled eye drops, excessively fill the conjunctival sac, cavity between the eye and the eyelids, causing a substantial part of the drop of eye drops is lost due to overflow at the edge of the Eyelid towards the cheek. In addition, a substantial part of the drop of eye drops left on the ocular surface crawls along the tears in the tear drain system, thus diluting the drug concentration It's not just about the dose quota of the drug lost before it crossed the cornea, but of the excess drug that can be transported to the nose and the throat in which it is absorbed in the general circulation, sometimes leading to serious systemic side effects. The small part of the drug in the drop of eye drops that does penetrate the cornea results in an initial peak tissue concentration, a higher level than required for the initial pharmacological effect. The tissue concentration then decreases gradually, so that when it is the turn of the next drop of eye drops, the visual concentration and the desired pharmacological effect can be too low
To aggravate the problems described Previously, patients often do not use their eye drops As they are prescribed. Often, this poor compliance is due to a burning sensation or initial burning caused by eye drops. Certainly, the instillation of eye drops in the eye itself can be difficult, partly because of the normal reflex to protect the eye. By Therefore, sometimes one or more drops leave the eye. The patients older people may have additional problems with instillation of the drops due to arthritis, tremors and decreased vision, and pediatric and psychiatric patient populations They also pose difficulties.
Attempts have been made to mitigate these limitations of topical medications through systems that They provide sustained release of the drug to the eye. The Previous topical sustained release systems include gradual release formulations, either as a solution or of ointment, which are applied to the eye in the same way as the eye drops but less frequently. Such formulations are described, for example, in U.S. Patent No. 3,826,258 issued to Abraham and U.S. Patent No. 4,923,699 granted to Kaufman. However, due to its application method, these formulations result in many of them problems detailed above for conventional eye drops. In In the case of ointment preparations, problems are encountered additional such as a blurred vision effect and discomfort of the feeling of stickiness produced by the dense base of the ointment.
Alternatively, sustained release systems have been configured to be placed at the bottom of the conjunctival sac, between the lower eyelid and the eye. Such units normally contain a reservoir containing the central drug surrounded by a hydrophobic copolymer membrane that controls the diffusion of the drug. Examples of such devices are described in U.S. Patent No. 3,618,604 issued to Ness, U.S. Patent No. 3,626,940 to Zaffaroni, U.S. Patent No. 3,845,770 to Theeuwes et al ., U.S. Patent No. 3,962,414. granted to Michaels, U.S. Patent No. 3,993,071 granted to Higuchi et al , and U.S. Patent No. 4,014,335 issued to Arnold. However, due to their placement, the units are uncomfortable and again there is little acceptance by the
Therefore, it is an object of the present invention provide an ophthalmic device and a method to Provide sustained release of medication to the eye.
It is another object of the present invention provide an ophthalmic device for use in order to ensure controlled administration of medication to the eye during An extended period of time.
It is still another object of the present invention provide an ophthalmic device for use in order to ensure sustained release of medication to the eye that improves the patient compliance
Consequently, an implant is provided ophthalmologic for sustained release of medication to the eye. He implant includes a body part sized to pass to through a tear point and to be placed inside a tear canaliculus of an eyelid. The implant also includes a collarete connected to the body part and sized for rest on the outside of the tear point, taking the collarete a pore provided in it. A deposit is contained at least partially within the body part and in communication fluid with the pore, in which the reservoir is designed to store and release the medication through the pore and into the eye over time in a controlled manner while the Implant is placed in the eyelid.
In the same way, a use is provided for provide sustained release of medication to the eye. He use includes providing an implant that has a body part sized to pass through a tear point and to placed inside a tear canalicle of an eyelid, a collarete connected to the body part and sized for rest on the outside of the tear point and it has a pore provided in it, and a deposit contained at least partially inside the body part and in fluid communication with the pore. The use also includes placing the implant in the tear point and eyelid canaliculus Still additionally, the method includes release the medication stored in the reservoir through the pore and towards the eye over time in a controlled way while the implant is placed in the eyelid.
In a preferred embodiment, the implant is placed in the superior tear point and canaliculus, so that the disturbance of the normal flow of tears be minimized. In addition, the pore is preferably constructed with a geometry specific appropriate to control the release rate of the medication to the eye. The implant may further comprise a elongated blister part connected to the body part for Hold the implant inside the canaliculus. The deposit can be partially contained within the blister part, and also may be in fluid communication with an extension of the deposit, such as a balloon, that extends into the interior of the canalicle to allow an additional volume of medication.
The previous objects and other objects, characteristics and advantages of the present invention are more understood easily from a review of the attached drawings and the description and the accompanying claims.
Figure 1 shows the anatomy of the system tear drainage of the human eye;
Figure 2 shows an example of an occluder conventional strut;
Figure 3 is a perspective view of the ophthalmic implant of the present invention;
Figure 4 is an illustration of the implant ophthalmologic when placed in the drainage system human tear;
Figure 5 is a cross-sectional view. of the ophthalmic implant that uses a prolongation of the Deposit;
Figure 6 is a cross-sectional view. of the ophthalmic implant that uses a wick extension from the deposit;
Figure 7 is a cross-sectional view. which shows the medication inside the implant reservoir ophthalmologic;
Figure 8 is a graph of the diffusion of the medication from the reservoir to the eye for different drug configurations within the reservoir; Y
Figure 9 is a schematic representation of a preferred medication configuration within the reservoir and its contact with the external tear flow.
As background, Figure 1 shows the Anatomy of the eye drainage system 10. Tears occur by the tear gland (not shown) above the part outside of each eye 10. Tears flow through the surface of eye 10 to a shallow accumulation zone, called lake 12 tear, located where the eyelids meet at its inner ends. From there, tears drain through small openings in each of the eyelids, specifically the upper tear point 14 and lower tear point 16. Since the upper 14 and lower 16 points, the tears pass to the upper tear canaliculus 18 and tear canaliculum 20 lower, respectively, which are duct-type pathways that they lead to tear bag 22. The tear bag 22 is the part upper, enlarged, nasolacrimal duct (not shown) that Drains tears to the nasal system. It is said that point 14 tear and upper canalicle 18 drain only approximately 10% of the tears of the eye 10, so that its obstruction It practically never leads to tears overflowing.
An insufficient amount of tears or "eye dry "is a common state produced by production insufficient tears from the tear gland which produces symptoms such as dryness, redness, burning, tearing reflex, itching or feeling of having a foreign body. In cases especially difficult dry eye, an occluder can be placed strut at one or both points 14, 16 tear. The occluders props prevent tears, which are occurring in a insufficient volume through the tear gland, drain into the 18, 20 tear ducts. Strut occluders can be held at lacrimal points 14, 16 without anesthesia and removed easily when necessary.
As shown in Fig. 2, a strut occluder 24 normally includes a collar 26 that rests on the outside of point 14, 16, a blister 28 projecting in a blocking manner towards the canaliculus 18, 20, and a portion 30 of body that connects the collar 26 and the blister 28. The commercially available strut occluders normally have a length of approximately 2.0 mm and differ from each other only slightly in their configuration. All its ampoules 28 are designed to prevent the occluder 24 from easily moving from the canaliculus 18, 20, and can be tapered to facilitate its insertion at points 14, 16. Its collarettes 26 are designed to have a diameter to prevent the occluder 24 is completely inserted into the canaliculus 18, 20, and preferably they are smooth to minimize irrigation of the eye 10. The body parts 30 of the different occluders 24 struts are similar and essentially constitute a non-functional connection between the collarette portions 26 and blister 28. The collar 26 may include an opening 31 that extends into the body part 30 to help grasp the occluder 24 during insertion at points 14, 16. Examples of strut occluders can be found in the patents. U.S. numbers 3,949,750 and 5,283,063 granted to Freeman, U.S. Patent Nos. 5,053,030; 5,171,270; and 5,723,005 issued to Herrick, U.S. Patent No. 5,417,651 issued to Guena et al , and U.S. Patent No. 5,423,777 issued to Tajiri et al .
Against this background, the device ophthalmic implant of the present invention, designated generally by reference number 32, it is illustrated in the Figure 3. In a preferred embodiment, the implant 32 ophthalmologic adapts to the shape of a strut 24 occluder conventional to incorporate a reservoir 34 designed to store and release medication towards the surface of the eye 10 in a way Continue, in the long term. The ophthalmic implant 32 may be molded or otherwise formed from a material flexible, such as silicone, which is impervious to medication that will fill the tank 34. The tank 34 is formed by a channel through the inside of an implant body part 36 32. Preferably, the body part 36 is flexible, and even It can be shaped accordion to provide the ability to Longitudinal prolongation when filled with medication.
Still with reference to figure 3, a collar 40 anchors implant 32 outside point 14, 16 tear, and is equipped with a pore 42 in fluid communication with deposit 34. In order to control the administration of a specific medication, the geometry of the pore 42 can be adapted as will be explained later. Through the pore 42, the medication It is distributed from reservoir 34 to the tears of Lake 12 tear, in which the medication is mixed, just as it does eye drops, with tears and penetrates eye 10 to have the desired pharmacological effect Although not necessary, it can provide an elongated blister part 38 to help hold the implant 32 inside the canalicule 18 and also to provide additional volume to reservoir 34 as it is sample.
Figure 4 shows the ophthalmic implant 34 of the present invention filled with medication and placed in the upper tear drainage system. Unlike the sustained-release devices of the prior art, the ophthalmic implant 32 of the present invention improves the patient compliance through comfortable placement in a relatively non-essential eye hole. The implant placement 32 at tear point 14 and canaliculus 18 higher, as shown, due to its low percentage of tear drainage compared to the drainage system lower tear. With this placement, implant 32 ophthalmologic can perform its sustained release function without affect the normal flow of tears.
As with strut occluders conventional, implant 32 can be placed and removed in a manner Non surgical and without anesthesia. In practice, channel 18 is prepares for implant placement 32 through dilation With a conical rod. Channel 18 is surrounded by tissue elastic that allows it to expand to allow the entry of implant 32, and subsequently resume a tight hold on the implant 32 to prevent accidental removal. Behind the dilation, an insertion tool similar to tweezers to place implant 32 at point 14. The implant 32 ophthalmologic can be placed in point 14 previously filled with medication, or alternatively it can be filled after placement from a syringe type device. The latter method is advantageous because implant 32 could be refilled with medication without requiring its extraction. When desired remove the implant 32 from point 14, the collar 40 clings easily with the tweezers, force is applied and the implant.
In order to increase the volume of the deposit 34 beyond that available in body part 36 and ampoule 38 of the ophthalmic implant 32, an extension can be provided 44 of the tank in fluid communication with the tank 34, such as is shown in figure 5. In a preferred embodiment, the extension 44 of the tank comprises an expandable component, of balloon type, which extends into the interior of canalicle 18. The extension 44 of the tank can be molded as one piece solidarity of implant 32, or alternatively it can be attached to the body part 36 or blister 38 as an additional piece.
In the realization of ophthalmic implant 32 shown in figure 6, an extension 46 of wick from reservoir 34 to aid in the release of the medication towards the surface of the eye 10. The extension 46 of wick is preferably held within reservoir 34 in fluid communication with the medication stored in it, and it extends through the pore 42 in the collar 40 to rest in the tear lake 12. The wick extension 46 must be formed of a suitable material to transmit the medication from the reservoir 34 to the tear lake 12, preferably a material absorbent, cloth type, which can rest on lake 12 tear without causing irritation. The use of extension 46 of wick ensures constant contact of implant 32 with the tear stream and also provides additional help for implant removal 32.
Figure 7 shows the ophthalmic implant 32 of the present invention with its reservoir 34 filled with the medication. Transfer of medication from the reservoir 34 towards the surface of the eye 10 takes place by diffusion. Be define a gradient region (g) by the length from the deposit 34 to the exit of the pore 42. The medication flows along the gradient (g), through pore 42 that has an area (A) of cross section, and towards tears in tear lake 12 that they replace medication through the diffusion process. Depending on the concentration of medication required in the tears, the medication may be in the form of a solid, a concentrated or other aqueous solution, a resin suspension, encapsulated within biodegradable microspheres such as liposomes or other suitable compound nanomaterials, or in a combination of these different configurations.
Dissemination of medication outside the depot 34 is controlled by the following equations, Fick's laws dissemination:
in which c represents the concentration, D represents the diffusion coefficient, J is the flow density (flow per unit cross-sectional area), x is the distance along the direction of the flow, and t is the weather. For the ophthalmic implant 32 of the present invention, equation 2 becomes in:
in which c_ {i} is the medication concentration within reservoir 34 adjacent to its pore 44, and c_ {o} is the concentration of medication in the tears just outside the reservoir 34. The value of c_ {o} is very next to zero if the flow of tears in tear lake 12 drag the medication from the pore 44.
Figure 8 is a graph of the diffusion of the medication from reservoir 34 towards tear lake 12 for Different medication settings. The diffusion of a phase single, or concentration, of medication within reservoir 34 is indicated by reference number 48. As shown, so soon as the diffusion process begins, the concentration, c_ {i}, and the flow, J, change over time, so that the rate Medication administration decreases exponentially by first order chemical kinetics. Advantageously, it can a variety of drug configurations be used in the depot to meet the needs of different patients or to the needs of change over a patient's time individual.
In a preferred embodiment shown schematically in figure 9, the reservoir 34 includes a region (a) that contains the most concentrated form of medication, either in solid or liquid state. The medication diffuses from the region (a) towards an adjacent region (b), closer to pore 42, that It contains a saturated solution of the medication. Preferably, the concentrated form of medication in region (a) must be moderately soluble in saline or water, in order to guarantee a region (b) constantly saturated. With reference back to figure 8, the diffusion of this two configuration phases are indicated by reference number 50. The Two-phase configuration will cause the release rate of the medication is constant, since the medication concentrated on the region (a) maintains a constant saturated concentration, c_ {i}, in the region (b). The saturated solution (b) will remain saturated as the medication is released whenever it is present the concentrated form in region (a). In the example shown in figure 8, the concentrated medication is depleted in the time t_ {x}.
The geometry of the pore 42 that leads from the reservoir 34 until the tear lake 12 controls the flow rate, I, of medication from ophthalmologic implant 32 by:
Therefore, for a given diffusion coefficient, D, and a given concentration of the medication in the saturated phase, c_ {i}, I is controlled by pore geometry 42 (A / g). Using this information, the geometry can be calculated appropriate pore 42 necessary to achieve a flow rate of Desired medication over time. The pore 42 that controls the rate can be formed with specific dimensions at the time that implant 32 is performed, or pore 42 could be sized properly by readjusting implant 32 with a cap provided with an opening of appropriate geometry coupled on the reservoir 34. In an alternative embodiment, pore 42 could be provided in the form of a non-perforated material located above collarette 40 that is permeable to the passage of medication.
Although the release of the medication from the Deposit 34 is mainly controlled by diffusion, factors Side effects such as gravity, the inertia of the rapid descending component of each blink and muscle forces inside the eyelid may favor the release of medication of reservoir 34. In addition, a micropump could be used within the 32 ophthalmic implant to forcefully expel the medication from deposit 34 at a chosen rate.
The replacement of eye drops with implant 32 Ophthalmologic of the present invention will enhance the convenience for patients who currently need long-term use of eye medication In addition, the implant of the present invention will eliminate the main problem of your medical treatment, the inconstant patient compliance. And what is more important, implant 32 of the present invention offers the patient the benefit of a continuous pharmacological effect, as opposed to Initial peak medication concentration and decrease gradual in the therapeutic action found with eye drops. By therefore, the quality of medical care will improve in those eye diseases that require prolonged use of eye medications
The four drugs against glaucoma plus currently important, each of which is supplied only as eye drops in aqueous solution, they are immediate candidates for administration through implant 32 of the present invention. The four drugs, specifically timolol, hydrochloride dorzolamide, latanoprost and brimonidine, are potent drugs, with long durations of action, demonstrated by its concentration relatively low in eye drops and its low frequency of administration (see: 1998 Physicians' Desk Reference for Ophthalmology).
When released using implant 32 of the present invention, some agents can now achieve effective concentrations in target tissues that are currently partially or completely inaccessible for topical application conventional. Possible agents to be released through the Implant 32 include those for antimicrobial treatment, including antiviral agents for herpes simplex, keratitis for herpes zoster and possibly cytomegalovirus retinitis, antifungal agents and antibiotics for keratitis and possibly endophthalmitis, anti-inflammatory medications steroids and non-steroids for many inflammatory diseases and inflammatory components of eye disorders, and new agents as those with neuroprotective properties for cells ganglion and / or axons of the optic nerve in glaucoma, as well as gene administration to eye tissues. In addition, the implant and the method of the present invention can make possible eye treatment with medications that are now not adequate for the formulation of eye drops, such as drugs that are chemically unstable in tears and therefore have a duration of action too short, or have other characteristics limiting
While they have been illustrated and described embodiments of the invention, it is not intended that these realizations illustrate and describe all possible forms of invention. On the contrary, the words used are words descriptive rather than limiting, and it is understood that they can various changes are made without departing from the spirit and scope of the invention.
1. Ophthalmic implant for release sustained medication to one eye, the implant having a part of body sized to pass through a tear point and to placed inside a tear canalicle of an eyelid, a collarete connected to the body part and sized for rest on the outside of the tear point, taking the collarete at least one pore provided in it, a deposit contained at least partially within the body part and in fluid communication with the at least one pore, where the use comprises the stages of:
Place the implant inside the point and tear canalicle of the eyelid; Y
release the medication stored inside the deposit through at least one pore and towards the eye along of time in a way.
2. The ophthalmic implant for use according to the claim 1, wherein the implant placement includes place the implant in a tear point and a canaliculus superior.
3. The ophthalmic implant for use according to the claim 1, wherein the implant placement includes place the prefilled implant with the medication.
4. The ophthalmic implant for use according to the claim 1, further comprising filling the implant with medication after placing the implant in the spot and tear canaliculus.
5. The ophthalmic implant for use according to the claim 1, wherein the release of the medication includes control the release rate of the medication into the eye by building the at least one pore with a geometry specific.
ES07012726T 1998-04-20 2000-04-07 Ophthalmological implant and method for sustained release of measurement to the eye. Active ES2340616T3 (en)
US09/294,720 US6196993B1 (en) 1998-04-20 1999-04-19 Ophthalmic insert and method for sustained release of medication to the eye
US294720 1999-04-19
ES2340616T3 true ES2340616T3 (en) 2010-06-07
ID=23134640
ES07012726T Active ES2340616T3 (en) 1998-04-20 2000-04-07 Ophthalmological implant and method for sustained release of measurement to the eye.
ES00921783T Active ES2288471T3 (en) 1998-04-20 2000-04-07 Ophthalmological implant and method for sustained release of eye medication.
US (1) US6196993B1 (en)
EP (2) EP1891942B1 (en)
AT (2) AT369843T (en)
AU (1) AU4205900A (en)
DE (2) DE60035979T2 (en)
DK (2) DK1178779T3 (en)
ES (2) ES2340616T3 (en)
PT (2) PT1178779E (en)
WO (1) WO2000062760A1 (en)
ES2250504T3 (en) 2000-11-29 2006-04-16 Allergan Inc. Prevention of rejection of graft in the eye.
FR2834446B1 (en) * 2002-01-08 2004-02-13 Ioltechnologie Production Expanding meatic nail
CA2478772C (en) 2002-03-11 2011-01-18 Alcon, Inc. Implantable drug delivery system
KR20050108345A (en) * 2003-01-24 2005-11-16 컨트롤 딜리버리 시스템즈 인코포레이티드 Sustained release and method for ocular delivery of carbonic anhydrase inhibitors
AT440595T (en) * 2003-01-24 2009-09-15 Psivida Inc Extended release device and method for the organic administration of adrenergen agents
EP1656116A4 (en) * 2003-08-22 2012-03-28 Vista Scient Llc Polymeric systems for controlled drug therapy
CA2573892A1 (en) * 2004-07-26 2006-02-09 Clarity Corporation Implantable device having reservoir with controlled release of medication and method of manufacturing the same
EP1937314A4 (en) * 2005-09-01 2009-01-07 Squibb Bristol Myers Co Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
CN103393483B (en) * 2006-03-31 2016-08-24 玛提治疗有限公司 Medicine release method, structure and composition for nose tear system
BRPI0713719A2 (en) * 2006-06-21 2012-10-30 Johnson & Johnson Vision Care punctual plugs for delivery of active agents
US8969622B2 (en) * 2006-08-23 2015-03-03 Vanderbilt University Dendritic molecular intracellular transporters and methods of making and using same
CA2698508C (en) * 2007-09-07 2017-06-06 Alan R. Rapacki Lacrimal implants and related methods
MX2010002619A (en) * 2007-09-07 2010-06-01 Qlt Plug Delivery Inc Lacrimal implant detection.
AU2008300013A1 (en) 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
CA3007559A1 (en) 2007-11-05 2009-05-14 Vanderbilt University Methods of prepararing epoxide-functionalized polymers
US20110274620A1 (en) * 2007-11-05 2011-11-10 Harth Eva M Multifunctional degradable nanoparticles with control over size and functionalities
WO2009097468A2 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
JP5528356B2 (en) * 2008-02-18 2014-06-25 キュー エル ティー インク．ＱＬＴ Ｉｎｃ． Lacrimal implant and related methods
JP5552482B2 (en) 2008-04-30 2014-07-16 キュー エル ティー インク．ＱＬＴ Ｉｎｃ． Composite lacrimal insert and related methods
TWI542338B (en) * 2008-05-07 2016-07-21 壯生和壯生視覺關懷公司 Ophthalmic devices for the controlled release of active agents
BRPI0912182A2 (en) * 2008-05-09 2015-10-06 Qlt Plug Delivery Inc prolonged release distribution of active agents to treat glaucoma and ocular hypertension
SG173069A1 (en) * 2009-01-23 2011-08-29 Quadra Logic Tech Inc Sustained released delivery of one or more agents
US20100233241A1 (en) * 2009-03-13 2010-09-16 Vista Scientific Llc Ophthalmic drug delivery system and applications
TW201043211A (en) * 2009-03-31 2010-12-16 Johnson & Johnson Vision Care Inc Punctal plugs
US20120157938A1 (en) 2010-12-16 2012-06-21 Tokarski Jason M Punctal plug with drug core retention features
EP2750660B1 (en) 2011-08-29 2016-10-12 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
KR102039468B1 (en) 2011-12-05 2019-11-01 인셉트, 엘엘씨 Medical organogel processes and compositions
US8808256B2 (en) * 2012-01-16 2014-08-19 Johnson & Johnson Vision Care, Inc. Eye drug delivery system
US20130220346A1 (en) 2012-02-28 2013-08-29 Victor Lust Balloon punctal plug
US20160302965A1 (en) * 2013-12-06 2016-10-20 Forsight Vision4, Inc. Implantable therapeutic devices
KR20170106298A (en) 2014-11-10 2017-09-20 포사이트 비젼4, 인크. Expandable drug delivery devices and methods of use
CA3024912A1 (en) * 2016-05-20 2017-11-23 The Regents Of The University Of Colorado, A Body Corporate Lacrimal drug delivery device
US3626940A (en) 1969-05-02 1971-12-14 Alza Corp Ocular insert
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3992071A (en) 1975-04-01 1976-11-16 The United States Of America As Represented By The Secretary Of The Army Processes for activating S-1 cathode
CA2031960C (en) * 1989-12-19 2002-05-28 Daniel Py Ocular treatment apparatus
US5417682A (en) 1991-01-30 1995-05-23 Alza Corporation Device for administering active agent to biological environment
1999-04-19 US US09/294,720 patent/US6196993B1/en not_active Expired - Lifetime
2000-04-07 EP EP07012726A patent/EP1891942B1/en active Active
2000-04-07 AU AU42059/00A patent/AU4205900A/en not_active Abandoned
2000-04-07 DK DK00921783T patent/DK1178779T3/en active
2000-04-07 ES ES07012726T patent/ES2340616T3/en active Active
2000-04-07 EP EP20000921783 patent/EP1178779B1/en not_active Revoked
2000-04-07 PT PT00921783T patent/PT1178779E/en unknown
2000-04-07 AT AT00921783T patent/AT369843T/en unknown
2000-04-07 WO PCT/US2000/009164 patent/WO2000062760A1/en active IP Right Grant
2000-04-07 DE DE2000635979 patent/DE60035979T2/en active Active
2000-04-07 PT PT07012726T patent/PT1891942E/en unknown
2000-04-07 DK DK07012726.1T patent/DK1891942T3/en active
2000-04-07 ES ES00921783T patent/ES2288471T3/en active Active
2000-04-07 AT AT07012726T patent/AT459343T/en unknown
2000-04-07 DE DE2000643959 patent/DE60043959D1/en active Active
EP1178779A1 (en) 2002-02-13
EP1891942A1 (en) 2008-02-27
ES2288471T3 (en) 2008-01-16
AT369843T (en) 2007-09-15
DE60043959D1 (en) 2010-04-15
DE60035979D1 (en) 2007-09-27
DK1891942T3 (en) 2010-06-07
WO2000062760A1 (en) 2000-10-26
US6196993B1 (en) 2001-03-06
EP1178779A4 (en) 2005-01-12
EP1891942B1 (en) 2010-03-03
AU4205900A (en) 2000-11-02
PT1891942E (en) 2010-04-21
DK1178779T3 (en) 2007-12-10
AT459343T (en) 2010-03-15
PT1178779E (en) 2007-10-02
DE60035979T2 (en) 2007-12-20
EP1178779B1 (en) 2007-08-15
AU764226B2 (en) 2003-08-14 Ophthalmic drug delivery device
ES2609594T3 (en) 2017-04-21 Drainage device to treat glaucoma
ES2312456T3 (en) 2009-03-01 Devices for intraocular supply of pharmacos.
Bill 1985 Some aspects of the ocular circulation. Friedenwald lecture.
EP0522008B1 (en) 1994-12-21 Canalicular implant having collapsible section
US20130331761A1 (en) 2013-12-12 Methods and Apparatus for Treating Glaucoma
JP5956626B2 (en) 2016-07-27 Anterior eye drug supply
JP2009523545A (en) 2009-06-25 Drug administration device
DE60225822T2 (en) 2009-04-16 Device for the administration of medicaments by intraocular iontophoresis or electroporation